Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1+/FLT3‐ITD+ acute myeloid leukemia: A pediatric case report
- 25 March 2023
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (7) , e30308
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7222056)
This publication has 5 references indexed in Scilit:
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialThe Lancet Oncology, 2020
- Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemiaPediatric Blood & Cancer, 2020
- MutatedWT1,FLT3-ITD,andNUP98-NSD1Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid LeukemiaJournal of Oncology, 2019
- Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemiaLeukemia, 2018
- Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2013